MAPT and Alzheimer disease: This presumptive impairment of the REM onset mechanism in AppNL-G-F mice may correspond to the increased REM latency in AD patients (Pase et al., 2017) that has recently associated with higher Aβ burden, phosphorylated tau-181 (p-tau181), and lower brain-derived neurotrophic factor (BDNF) levels (Jin et al., 2025).